Thymosin Beta-4

Thymosin beta-4 (timbetasin) is an investigational 43-amino-acid peptide that acts as the principal intracellular G-actin sequestering protein while exhibiting extracellular pro-regenerative effects, including promotion of wound healing, angiogenesis, tissue repair, and reduction of inflammation and fibrosis.

Brief glance

The primary outcome is Recovery & Repair, but it's also used for Performance, Immune Support. This compound is considered a Peptide. It is not currently indicated as compoundable in 503A pharmacies. It is not listed under a DEA schedule.

Overview

Thymosin beta-4 is a naturally occurring low molecular weight peptide that plays a vital role in cellular repair and regeneration through mechanisms including cell migration, angiogenesis, and wound healing. This regenerative peptide is being investigated clinically for treatment of dermal wounds, corneal injuries, myocardial infarction, acute lung injury, and pressure ulcers, with its therapeutic action mediated through anti-inflammatory, anti-apoptotic, and tissue-remodeling pathways. Current clinical and preclinical research has demonstrated efficacy in accelerating wound healing, promoting cardiac repair following ischemic events, and reducing inflammation across multiple tissue systems, though further clinical trials are needed to establish full safety and efficacy profiles across its various indications.

Thymosin Beta-4 (Tβ4), with the recommended International Nonproprietary Name timbetasin, is a 43-amino-acid peptide encoded by the TMSB4X gene and recognized as the principal intracellular G-actin sequestering protein in mammalian tissues except red blood cells. It regulates actin polymerization, promoting cell proliferation, migration, differentiation, wound healing, angiogenesis, and tissue repair while reducing inflammation, fibrosis, and scar formation. As an active pharmaceutical ingredient, Tβ4 has been investigated in clinical trials for applications such as dermal wound repair, corneal injuries, cardiac tissue regeneration post-myocardial infarction, and soft tissue injuries including tendons and ligaments. Its mechanisms include upregulating actin-related proteins, enhancing endothelial cell migration, and modulating pathways like PI3K/Akt and NF-κB to support cytoprotection and repair processes.

Benefits

Thymosin Beta-4 promotes wound healing and tissue repair by binding to actin to facilitate cell migration, angiogenesis, and stem cell differentiation while reducing inflammation, scar formation, and fibrosis.¹,²,³,⁴ Clinically, it has shown potential in accelerating recovery from soft tissue injuries, surgical wounds, corneal damage, and dry eye disorders, with human trials demonstrating reduced ocular inflammation and improved healing outcomes.¹,⁴ It also supports cardiac repair post-myocardial infarction by enhancing myocyte survival and vascular regeneration, and exhibits neuroprotective effects in traumatic brain injury models.²,⁴,⁵ Additional evidence indicates benefits in modulating immune responses and preventing excessive fibrosis in various tissues.³,⁶ Ongoing research explores its role in conditions like neurodegenerative diseases, though further clinical trials are needed to confirm efficacy and safety.¹

Side effects

Thymosin Beta-4 (TB4) is a 43-amino-acid peptide used therapeutically to promote wound healing, tissue repair, and angiogenesis by attracting stem and progenitor cells to injured areas and suppressing pro-inflammatory cytokines⁷. The most common side effects are generally mild and localized, including injection site reactions such as redness, pain, swelling, or irritation, particularly with larger needles or in injection-sensitive individuals⁴,⁸. Systemic side effects, though typically transient, may include temporary fatigue, headaches, dizziness, mild gastrointestinal discomfort, and occasionally a head rush, particularly in first-time users or with improper administration⁴,⁸. Rare but more serious adverse events reported include fever (≥100.4°F), injection site blistering, muscle aches, skin rash, vomiting, severe itching, or hives, which warrant discontinuation and immediate physician contact⁴. Critical safety considerations include contraindication in pregnant or breastfeeding individuals due to lack of safety data, and in those with suspected or active cancer, as TB4 stimulates angiogenesis which may theoretically support tumor growth⁴. Long-term human safety data remains limited, and potential drug interactions have not been comprehensively studied; therefore, thymosin beta-4 should be used only under physician supervision with medical-grade formulations, and treatment should not exceed 3 months without cycling⁴,⁹. To minimize adverse effects, practitioners recommend starting with lower doses, rotating injection sites, maintaining hydration, taking the peptide with food if gastrointestinal symptoms occur, and maintaining regular contact with the prescribing physician⁴.

Mechanisms of action

Thymosin Beta-4 is a 43-amino-acid peptide that primarily acts as an actin-sequestering protein, binding to monomeric G-actin to regulate its polymerization into filamentous F-actin, thereby influencing cell motility, structure, and migration.⁹,¹⁰,¹¹ This mechanism supports cytoskeletal dynamics essential for processes like wound repair and tissue regeneration.¹¹,¹² Additionally, it exhibits anti-inflammatory effects by inhibiting cytokine release, promotes angiogenesis through endothelial cell proliferation and VEGF upregulation, and reduces apoptosis to aid cell survival.⁹,¹⁰,¹³ These actions position Thymosin Beta-4 as a modulator in regenerative therapies, particularly for wound healing and ischemic conditions.¹⁰,¹²